Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yolanda Martín is active.

Publication


Featured researches published by Yolanda Martín.


The Journal of Molecular Diagnostics | 2011

A highly sensitive genetic protocol to detect NF1 mutations.

María Carmen Valero; Yolanda Martín; Elisabete Hernández-Imaz; Alba Marina Hernández; German Melean; Ana Valero; Francisco Javier Rodríguez-Álvarez; Dolores Tellería; Concepción Hernández-Chico

Neurofibromatosis type 1 (NF1) is a hereditary disorder caused by mutations in the NF1 gene. Detecting mutation in NF1 is hindered by the genes large size, the lack of mutation hotspots, the presence of pseudogenes, and the wide variety of possible lesions. We developed a method for detecting germline mutations by combining an original RNA-based cDNA-PCR mutation detection method and denaturing high-performance liquid chromatography (DHPLC) with multiplex ligation-dependent probe amplification (MLPA). The protocol was validated in a cohort of 56 blood samples from NF1 patients who fulfilled NIH diagnostic criteria, identifying the germline mutation in 53 cases (95% sensitivity). The efficiency and reliability of this approach facilitated detection of different types of mutations, including single-base substitutions, deletions or insertions of one to several nucleotides, microdeletions, and changes in intragenic copy number. Because mutational screening for minor lesions was performed using cDNA and the characterization of mutated alleles was performed at both the RNA and genomic DNA level, the analysis provided insight into the nature of the different mutations and their effect on NF1 mRNA splicing. After validation, we implemented the protocol as a routine test. Here we present the overall unbiased spectrum of NF1 mutations identified in 93 patients in a cohort of 105. The results indicate that this protocol is a powerful new tool for the molecular diagnosis of NF1.


Human Mutation | 2015

High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype–Phenotype Correlation

Kitiwan Rojnueangnit; Jing Xie; Alicia Gomes; Angela Sharp; Tom Callens; Yunjia Chen; Ying Liu; Meagan Cochran; Mary Alice Abbott; Joan F. Atkin; Dusica Babovic-Vuksanovic; Christopher Barnett; Melissa Crenshaw; Dennis Bartholomew; Lina Basel; Gary Bellus; Shay Ben-Shachar; Martin G. Bialer; David P. Bick; Bruce Blumberg; Fanny Cortés; Karen L. David; Anne Destrée; Anna Duat-Rodriguez; Dawn Earl; Luis F. Escobar; Marthanda Eswara; Begona Ezquieta; Ian Frayling; Moshe Frydman

Neurofibromatosis type 1 (NF1) is one of the most frequent genetic disorders, affecting 1:3,000 worldwide. Identification of genotype–phenotype correlations is challenging because of the wide range clinical variability, the progressive nature of the disorder, and extreme diversity of the mutational spectrum. We report 136 individuals with a distinct phenotype carrying one of five different NF1 missense mutations affecting p.Arg1809. Patients presented with multiple café‐au‐lait macules (CALM) with or without freckling and Lisch nodules, but no externally visible plexiform neurofibromas or clear cutaneous neurofibromas were found. About 25% of the individuals had Noonan‐like features. Pulmonic stenosis and short stature were significantly more prevalent compared with classic cohorts (P < 0.0001). Developmental delays and/or learning disabilities were reported in over 50% of patients. Melanocytes cultured from a CALM in a segmental NF1‐patient showed two different somatic NF1 mutations, p.Arg1809Cys and a multi‐exon deletion, providing genetic evidence that p.Arg1809Cys is a loss‐of‐function mutation in the melanocytes and causes a pigmentary phenotype. Constitutional missense mutations at p.Arg1809 affect 1.23% of unrelated NF1 probands in the UAB cohort, therefore this specific NF1 genotype–phenotype correlation will affect counseling and management of a significant number of patients.


American Journal of Human Genetics | 2018

Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844–848

Magdalena Koczkowska; Yunjia Chen; Tom Callens; Alicia Gomes; Angela Sharp; Sherrell Johnson; Meng Chang Hsiao; Zhenbin Chen; Meena Balasubramanian; Christopher Barnett; Troy A. Becker; Shay Ben-Shachar; Débora Romeo Bertola; Jaishri O. Blakeley; Emma Burkitt-Wright; Alison Callaway; Melissa Crenshaw; Karin S. Cunha; Mitch Cunningham; Maria Daniela D'Agostino; Karin Dahan; Alessandro De Luca; Anne Destrée; Radhika Dhamija; Marica Eoli; D. Gareth Evans; Patricia Galvin-Parton; Jaya K. George-Abraham; Karen W. Gripp; Jose Guevara-Campos

Neurofibromatosis type 1 (NF1), a common genetic disorder with a birth incidence of 1:2,000–3,000, is characterized by a highly variable clinical presentation. To date, only two clinically relevant intragenic genotype-phenotype correlations have been reported for NF1 missense mutations affecting p.Arg1809 and a single amino acid deletion p.Met922del. Both variants predispose to a distinct mild NF1 phenotype with neither externally visible cutaneous/plexiform neurofibromas nor other tumors. Here, we report 162 individuals (129 unrelated probands and 33 affected relatives) heterozygous for a constitutional missense mutation affecting one of five neighboring NF1 codons—Leu844, Cys845, Ala846, Leu847, and Gly848—located in the cysteine-serine-rich domain (CSRD). Collectively, these recurrent missense mutations affect ∼0.8% of unrelated NF1 mutation-positive probands in the University of Alabama at Birmingham (UAB) cohort. Major superficial plexiform neurofibromas and symptomatic spinal neurofibromas were more prevalent in these individuals compared with classic NF1-affected cohorts (both p < 0.0001). Nearly half of the individuals had symptomatic or asymptomatic optic pathway gliomas and/or skeletal abnormalities. Additionally, variants in this region seem to confer a high predisposition to develop malignancies compared with the general NF1-affected population (p = 0.0061). Our results demonstrate that these NF1 missense mutations, although located outside the GAP-related domain, may be an important risk factor for a severe presentation. A genotype-phenotype correlation at the NF1 region 844–848 exists and will be valuable in the management and genetic counseling of a significant number of individuals.


Neurogenetics | 2012

RNA-based analysis of two SMARCB1 mutations associated with familial schwannomatosis with meningiomas

German Melean; Ana Velasco; Elisabete Hernández-Imaz; Francisco Javier Rodríguez-Álvarez; Yolanda Martín; Ana Valero; Concepción Hernández-Chico

Germline mutations in the SMARCB1 gene cause familial schwannomatosis, a condition characterized by the presence of multiple schwannomas, although mutations in SMARCB1 have also been associated with rhadboid tumor predisposition syndrome 1 (RTPS1). Both schwannomatosis and RTPS1 are autosomal dominant conditions that predispose individuals to develop distinct types of tumors. We clinically and genetically characterized two families with schwannomatosis associated with SMARCB1 mutations. Eight affected members of these families developed different numbers of schwannomas and/or meningiomas at distinct ages, evidence that meningiomas are variably expressed in this condition. We identified two germline mutations in SMARCB1 associated with the familial disease, c.233-1G>A and the novel c.207_208dupTA mutation, which both proved to affect the main SMARCB1 isoforms at the RNA level distinctly. Interestingly, the c.207_208dupTA mutation had no effect on the coding sequence, pre-mRNA splicing or the level of expression of the SMARCB1 isoform 2. Furthermore, SMARCB1 isoforms harboring a premature termination codon were largely eliminated via the nonsense-mediated mRNA decay pathway. Our results highlight the importance of RNA-based studies to characterize SMARCB1 germline mutations in order to determine their impact on protein expression and gain further insight into the genetic basis of conditions associated with SMARCB1 mutations.


PLOS ONE | 2015

Functional Analysis of Mutations in Exon 9 of NF1 Reveals the Presence of Several Elements Regulating Splicing.

Elisabete Hernández-Imaz; Yolanda Martín; Laura De Conti; German Melean; Ana Valero; Marco Baralle; Concepción Hernández-Chico

Neurofibromatosis type 1 (NF1) is one of the most common human hereditary disorders, predisposing individuals to the development of benign and malignant tumors in the nervous system, as well as other clinical manifestations. NF1 is caused by heterozygous mutations in the NF1 gene and around 25% of the pathogenic changes affect pre-mRNA splicing. Since the molecular mechanisms affected by these mutations are poorly understood, we have analyzed the splicing mutations identified in exon 9 of NF1, which is particularly prone to such changes, to better define the possible splicing regulatory elements. Using a minigene approach, we studied the effect of five splicing mutations in this exon described in patients. These highlighted three regulatory motifs within the exon. An in vivo splicing analysis of an extensive collection of changes generated in the minigene demonstrated that the CG motif at c.910-911 is critical for the recognition of exon 9. We also found that the GC motif at c.945-946 is involved in exon recognition through SRSF2 and that this motif is part of a Composite Exon Splicing Regulatory Element made up of physically overlapping enhancer and silencer elements. Finally, through an in vivo splicing analysis and in vitro binding assays, we demonstrated that the c.1007G>A mutation creates an Exonic Splicing Silencer element that binds the hnRNPA1 protein. The complexity of the splicing regulatory elements present in exon 9 is most likely responsible for the fact that mutations in this region represent 25% of all exonic changes that affect splicing in the NF1 gene.


Expert Review of Molecular Diagnostics | 2011

Progress and challenges in developing a molecular diagnostic test for neurofibromatosis type 1.

Yolanda Martín; Ana Dopazo; Concepción Hernández-Chico

Neurofibromatosis type 1 (NF1; MIM 162200) is one of the most common human autosomal dominant disorders, with an estimated incidence of one per 3500 live births. The main clinical features of this condition are multiple neurofibromas, café-au-lait spots, axillary freckling, Lisch nodules, tibial pseudarthrosis, and a predisposition to develop certain benign and malignant tumors in the nervous system [1]. NF1 is caused by heterozygous mutations in the NF1 gene (NF1; NM_000267.2), which encodes neurofibromin, a negative regulator of Ras-mediated signaling. NF1 is a classic tumor suppressor gene as its biallelic inactivation causes tumor development [2].


Genetics in Medicine | 2018

Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype–phenotype correlation

Magdalena Koczkowska; Tom Callens; Alicia Gomes; Angela Sharp; Yunjia Chen; Alesha D. Hicks; Arthur S. Aylsworth; Amedeo A. Azizi; Donald Basel; Gary Bellus; Lynne M. Bird; Maria Blazo; Leah W. Burke; Ashley Cannon; Felicity Collins; Colette DeFilippo; Ellen Denayer; Maria Cristina Digilio; Shelley K. Dills; Laura Dosa; Robert S. Greenwood; Cristin Griffis; Punita Gupta; Rachel K. Hachen; Concepción Hernández-Chico; Sandra Janssens; Kristi J. Jones; Justin T. Jordan; Peter Kannu; Bruce R. Korf

PurposeNeurofibromatosis type 1 (NF1) is characterized by a highly variable clinical presentation, but almost all NF1-affected adults present with cutaneous and/or subcutaneous neurofibromas. Exceptions are individuals heterozygous for the NF1 in-frame deletion, c.2970_2972del (p.Met992del), associated with a mild phenotype without any externally visible tumors.MethodsA total of 135 individuals from 103 unrelated families, all carrying the constitutional NF1 p.Met992del pathogenic variant and clinically assessed using the same standardized phenotypic checklist form, were included in this study.ResultsNone of the individuals had externally visible plexiform or histopathologically confirmed cutaneous or subcutaneous neurofibromas. We did not identify any complications, such as symptomatic optic pathway gliomas (OPGs) or symptomatic spinal neurofibromas; however, 4.8% of individuals had nonoptic brain tumors, mostly low-grade and asymptomatic, and 38.8% had cognitive impairment/learning disabilities. In an individual with the NF1 constitutional c.2970_2972del and three astrocytomas, we provided proof that all were NF1-associated tumors given loss of heterozygosity at three intragenic NF1 microsatellite markers and c.2970_2972del.ConclusionWe demonstrate that individuals with the NF1 p.Met992del pathogenic variant have a mild NF1 phenotype lacking clinically suspected plexiform, cutaneous, or subcutaneous neurofibromas. However, learning difficulties are clearly part of the phenotypic presentation in these individuals and will require specialized care.


Human Genetics | 2009

Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene

Laura Alías; Sara Bernal; Pablo Fuentes-Prior; Mj Barcelo; Eva Also; Rebeca Martínez-Hernández; Francisco Javier Rodríguez-Álvarez; Yolanda Martín; Elena Aller; Elena Grau; Ana Peciña; Guillermo Antiñolo; Enrique Galán; Alberto L. Rosa; Miguel Fernández-Burriel; Salud Borrego; José M. Millán; Concepción Hernández-Chico; Montserrat Baiget; Eduardo F. Tizzano


Human Genetics | 2002

Genetic study of SMA patients without homozygous SMN1 deletions: identification of compound heterozygotes and characterisation of novel intragenic SMN1 mutations.

Yolanda Martín; Ana Valero; Emilia del Castillo; Samuel I. Pascual; Concepción Hernández-Chico


Human Genetics | 2001

Characterisation of SMN hybrid genes in Spanish SMA patients: de novo, homozygous and compound heterozygous cases.

Ivón Cuscó; Mj Barcelo; Elisabeth del Río; Yolanda Martín; Concepción Hernández-Chico; Elena Bussaglia; Montserrat Baiget; Eduardo F. Tizzano

Collaboration


Dive into the Yolanda Martín's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

German Melean

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar

Alicia Gomes

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar

Angela Sharp

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar

Tom Callens

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar

Yunjia Chen

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Montserrat Baiget

Autonomous University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge